Traders should expect upward price pressure as the market digests the positive clinical validation. Monitor for regulatory submission milestones and potential partnership or M&A interest given the high unmet need.
Price Chart
Executive Summary
Revolution Medicines announced that Phase 1/2 data for daraxonrasib in RAS-mutant pancreatic cancer were published in NEJM, complementing recently reported positive Phase 3 topline results showing an unprecedented overall survival benefit. The drug holds FDA Breakthrough Therapy and Orphan Drug Designations, reinforcing its potential as a new standard of care for a deadly cancer with limited treatment options.
Key Facts
- NEJM published Phase 1/2 data for daraxonrasib in metastatic RAS-mutant PDAC.
- Company previously announced positive Phase 3 RASolute 302 topline results with unprecedented overall survival benefit vs. standard chemotherapy.
- Daraxonrasib has FDA Breakthrough Therapy and Orphan Drug Designations for PDAC with G12 mutations.
- Daraxonrasib is a RAS(ON) multi-selective inhibitor targeting diverse RAS mutations.
- Three additional global Phase 3 registrational trials are ongoing, including earlier-line PDAC and NSCLC.
Financial Impact
Positive clinical data significantly increases probability of regulatory approval and peak sales potential, estimated by analysts in the multi-billion dollar range for PDAC indication alone.
Risk Factors
- Regulatory approval not guaranteed; pivotal trial results may not replicate in larger populations.
- Competition from other RAS inhibitors (e.g., from Mirati, Amgen) could limit market share.
- Risk of toxicity or safety issues in ongoing broader clinical development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.64 (+5.47%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.64 (+5.47%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.64 (+0.87%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.64 (+0.87%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.64 (−4.08%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.64 (−4.08%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.64 (−2.24%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.64 (+9.19%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.64 (+10.20%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.64 (+24.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access